Bridge Therapeutics has announced they will be expanding their operations into one of the finest locations in Birmingham, Alabama. The new headquarters at the Summit in Birmingham is currently under design by the award-winning architectural firm Chambless King Architects. “Our new headquarters will bring a new energy to Bridge Therapeutics,” said Alton Kelley, Director of Business Development….
Author: lisa@northstreetim.com
Aiming for an “overall reduction in opioid overuse and overdoses,” Medicare announces starting next year there will be new limits for high-dose opioid prescriptions. The Medicare announcement—part of the 2019 Medicare Advantage and Part D Rate Announcement and Call Letter— sets limits for opioid-naive patients on seven-day prescriptions, and notes the expansion and combination of the…
The innovative late development-stage pharmaceutical startup, Bridge Therapeutics has announced Tim Peara will be joining its management team as the new Director of Finance, effective immediately. Tim Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for…
Greg Sullivan, MD, Chief Scientific Officer and CEO of Bridge Therapeutics, was recently interviewed by Bronwyn Mixter of Bloomberg BNA about the abuse of gabapentinoid pain drugs. Dr. Sullivan explains how buprenorphine is a safe alternative for many of the dangerous drugs that are currently prescribed for chronic pain. In the article Dr. Sullivan discusses…
Managed Healthcare Executive published a story in January that gave medical doctors advice on how they can better address the opioid epidemic. The publication turned to the Chief Scientific Officer of Bridge Therapeutics, Greg Sullivan M.D., and other medical experts for their feature, Eight ways doctors can address the opioid epidemic. Dr. Sullivan, told the…
A recent article published on the website The Hill discusses the problem of prescribing addictive schedule III drugs for pain relief rather than the equally effective and non-addictive schedule II drugs.